BlackRock Inc. boosted its holdings in shares of Achillion Pharmaceuticals (NASDAQ:ACHN) by 17.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,572,015 shares of the biopharmaceutical company’s stock after acquiring an additional 1,736,124 shares during the quarter. BlackRock Inc. owned approximately 8.39% of Achillion Pharmaceuticals worth $33,326,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of ACHN. Teacher Retirement System of Texas bought a new position in Achillion Pharmaceuticals during the fourth quarter valued at approximately $109,000. Bourgeon Capital Management LLC raised its position in shares of Achillion Pharmaceuticals by 64.4% in the fourth quarter. Bourgeon Capital Management LLC now owns 48,504 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 19,004 shares during the period. SG Americas Securities LLC raised its position in shares of Achillion Pharmaceuticals by 59.8% in the third quarter. SG Americas Securities LLC now owns 42,229 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 15,800 shares during the period. Matisse Capital raised its position in shares of Achillion Pharmaceuticals by 15.8% in the fourth quarter. Matisse Capital now owns 135,445 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 18,500 shares during the period. Finally, Swiss National Bank raised its position in shares of Achillion Pharmaceuticals by 19.1% in the fourth quarter. Swiss National Bank now owns 189,800 shares of the biopharmaceutical company’s stock valued at $547,000 after purchasing an additional 30,400 shares during the period. 82.04% of the stock is currently owned by hedge funds and other institutional investors.
ACHN has been the topic of a number of recent analyst reports. BidaskClub raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 6th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, B. Riley initiated coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, February 8th. They issued a “neutral” rating and a $3.50 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. Achillion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $4.89.
NASDAQ:ACHN opened at $3.60 on Thursday. Achillion Pharmaceuticals has a 12 month low of $2.58 and a 12 month high of $5.66. The company has a market capitalization of $490.90, a PE ratio of -5.81 and a beta of 0.89.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). During the same period last year, the company earned ($0.03) EPS. sell-side analysts forecast that Achillion Pharmaceuticals will post -0.55 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “BlackRock Inc. Acquires 1,736,124 Shares of Achillion Pharmaceuticals (ACHN)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/12/blackrock-inc-acquires-1736124-shares-of-achillion-pharmaceuticals-achn.html.
Achillion Pharmaceuticals Profile
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.